Conjubrook: Advanced Relief for Chronic Neuropathic Pain
| Product dosage: 0.625mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 28 | $7.68 | $215.06 (0%) | 🛒 Add to cart |
| 56 | $6.77 | $430.13 $379.11 (12%) | 🛒 Add to cart |
| 84 | $6.45 | $645.19 $542.16 (16%) | 🛒 Add to cart |
| 112 | $6.30
Best per pill | $860.26 $705.21 (18%) | 🛒 Add to cart |
Conjubrook represents a significant advancement in the management of moderate to severe chronic neuropathic pain. This prescription medication, containing the active ingredient Pregabalin, is specifically formulated to modulate hyperexcited neurons, providing targeted relief where traditional analgesics often fall short. Its development is grounded in extensive clinical research, offering a well-tolerated option for patients suffering from conditions such as diabetic neuropathy, postherpetic neuralgia, and spinal cord injury-related pain. By stabilizing calcium channels in the central nervous system, Conjubrook reduces the release of several neurotransmitters, effectively diminishing pain signals and improving overall quality of life for individuals with persistent neuropathic discomfort.
Features
- Active Pharmaceutical Ingredient: Pregabalin (75mg, 150mg, 300mg film-coated tablets)
- Pharmacological Class: Gabapentinoid; Calcium Channel Modulator
- Mechanism of Action: Binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system
- Bioavailability: Greater than 90% and is independent of dose
- Time to Peak Plasma Concentration (Tmax): Approximately 1.5 hours post-administration
- Elimination Half-Life: ~6.5 hours
- Excretion: Primarily renal (90% unchanged in urine)
- Presentation: Blister packs of 14, 28, and 56 tablets
Benefits
- Provides significant and sustained reduction in neuropathic pain scores, as measured by visual analog scales (VAS).
- Improves sleep quality and duration by alleviating the pain that often disrupts rest, leading to better daily functioning.
- Enhances overall patient-reported outcomes, including mood and general activity levels, by effectively managing the primary pain source.
- Offers a predictable pharmacokinetic profile with linear absorption, allowing for consistent dosing and efficacy.
- Serves as a valuable adjunct or alternative therapy for patients who have experienced inadequate pain control with other medications.
Common use
Conjubrook is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, a condition characterized by burning, shooting, or stabbing pain in the extremities due to nerve damage from diabetes. It is also approved for the treatment of postherpetic neuralgia, the persistent pain that can follow an episode of shingles (herpes zoster). Furthermore, it is utilized in the management of neuropathic pain associated with spinal cord injury. Its use is reserved for cases where pain is moderate to severe and has proven refractory to first-line treatments.
Dosage and direction
The dosage of Conjubrook must be individualized according to the patient’s renal function and therapeutic response. The recommended starting dose for neuropathic pain is 150 mg per day, administered orally in two or three divided doses (e.g., 75 mg twice daily or 50 mg three times daily). Based on efficacy and tolerability, the dose may be increased to 300 mg per day after an interval of 3 to 7 days. If needed, and if well-tolerated, the dose can be further increased to a maximum of 600 mg per day after another week. Dosage adjustment is required for patients with reduced renal function (creatinine clearance < 60 mL/min). Conjubrook may be taken with or without food. Abrupt discontinuation should be avoided; the dose should be tapered gradually over a minimum of one week.
Precautions
Patients should be cautioned about the potential for dizziness, somnolence, and blurred vision, which could impair their ability to drive or operate machinery. This effect may be dose-related. Patients should be advised not to drive until they have sufficient experience with Conjubrook to gauge whether it adversely affects their abilities. Conjubrook may cause weight gain and peripheral edema; patients should be monitored for these effects, particularly those with comorbid conditions such as congestive heart failure or diabetes. There is a potential for misuse and abuse; therefore, a careful patient history should be taken for a history of substance abuse. Patients should be monitored for the emergence or worsening of depression, suicidal thoughts, or behavior.
Contraindications
Conjubrook is contraindicated in patients with a known hypersensitivity to pregabalin or any of the excipients in the formulation. Its use is also contraindicated in patients with severe congestive heart failure (NYHA Class IV) unless the potential benefit outweighs the significant risk of fluid retention-related complications.
Possible side effect
The most commonly observed adverse reactions (≥5% and twice the rate of placebo) are dizziness, somnolence, dry mouth, peripheral edema, blurred vision, weight gain, and difficulty with concentration/attention. Other reported side effects include euphoria, balance disorder, tremor, diplopia, nausea, constipation, and increased appetite. Most adverse reactions are mild to moderate in intensity and are often dose-dependent.
Drug interaction
Conjubrook has a low potential for pharmacokinetic drug interactions as it is not metabolized in the liver and does not inhibit major CYP enzymes. It is eliminated renally largely unchanged. However, pharmacodynamic interactions can occur. Conjubrook may potentiate the effects of ethanol and other CNS depressants (e.g., benzodiazepines, opioids, barbiturates). Coadministration with thiazolidinedione antidiabetic agents (e.g., pioglitazone) may potentiate the risk of weight gain and/or fluid retention. Any drug with sedative properties may enhance the neurocognitive effects of Conjubrook.
Missed dose
If a dose is missed, it should be taken as soon as it is remembered, unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped, and the patient should return to their regular dosing schedule. The dose should not be doubled to make up for a missed dose.
Overdose
In cases of overdose, the most expected effects would be an exaggeration of its known adverse reactions, including severe somnolence, lethargy, restlessness, agitation, confusion, and depression. There is no specific antidote for pregabalin overdose. Treatment should consist of general supportive measures, including ensuring an adequate airway and monitoring vital signs. Hemodialysis may be effective in removing pregabalin from the blood (approximately 50% removal over 4 hours) and should be considered in cases of significant overdose, especially in patients with renal impairment.
Storage
Store Conjubrook tablets at room temperature, between 20°C to 25°C (68°F to 77°F). Excursions are permitted between 15°C and 30°C (59°F and 86°F). Keep the blisters in the outer carton to protect from light and moisture. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging.
Disclaimer
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read here. The efficacy and safety data described are based on clinical trials; individual patient experiences may vary.
Reviews
“After struggling with diabetic neuropathy for years, Conjubrook has been a game-changer. The reduction in burning pain has allowed me to sleep through the night and regain a level of normalcy in my daily activities. The titration process was managed well by my neurologist.” – M.B., Patient (4.5/5 Stars)
“As a pain specialist, I find Conjubrook to be a reliable and effective option in my arsenal for neuropathic pain. Its predictable pharmacokinetics and generally favorable side effect profile make it a suitable choice for a wide range of patients who have not found success with gabapentin or TCAs.” – Dr. A. Sharma, MD (4/5 Stars)
“The efficacy is undeniable, but the side effect of significant weight gain has been a challenging trade-off to manage for some of my patients. It requires careful patient selection and ongoing monitoring of BMI and metabolic parameters.” – Clinical Pharmacist (3.5/5 Stars)